- NEUTRAL
Quarterly Revenue TransCode Therapeutics Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.
- NEGATIVE
Quarterly Net Profit TransCode Therapeutics Inc Jun-2026 Quarterly Net Profit is $-7 Million which is growth of -57.8% YoY.
1.760.11(6.67%)
66,108
XNAS Volume
XNAS 21 Sep, 2026 5:30 PM (EDT)
TransCode Therapeutics Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents
TransCode Therapeutics Inc quarterly results: revenue, profit, and P&L – 13 quarter history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
| Indicator | Graph | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Rev. | ||||||||||||||
Cost Of Rev. | - | - | - | - | - | - | - | - | - | - | - | - | - | |
Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | |
| 6.2 | 17.6 | 6.5 | 4.5 | 4.1 | 2.8 | 4.6 | 2.2 | 5.1 | 3.3 | 4 | 5.3 | 4.3 | ||
Operating Profit | -6.2 | -17.6 | -6.5 | -4.5 | -4.1 | -2.8 | -4.6 | -2.2 | -5.1 | -3.3 | -4 | -5.3 | -4.3 | |
| 0.1 | 0.1 | 0.1 | -0 | -0.6 | -0 | -0 | -0.1 | |||||||
Profit Before Tax | -6.8 | -17.6 | -13.2 | -4.9 | -4.3 | -12.1 | -5.9 | -2.3 | -5.2 | -3.3 | -4.1 | -5.3 | -4.3 | |
Tax | 0.2 | - | - | - | - | - | - | - | - | - | - | - | ||
| -6.9 | -19.5 | -15.1 | -4.9 | -4.3 | -12.1 | -6 | -2.3 | -5.2 | -3.3 | -4.1 | -5.3 | -4.3 | ||
Diluted NI Avail to Com Stockholders Ann. | -6.9 | -19.5 | -15.1 | -4.9 | -4.3 | -12.1 | -6 | -2.3 | -5.2 | -3.3 | -4.1 | -5.3 | -4.3 | |
Basic EPS | -7.2 | -21.3 | -18.1 | -5.8 | -5.1 | -70.3 | -161.8 | -147.8 | -683.8 | -600.6 | -6,020 | -18,339 | -83,493.3 | |
Diluted EPS After ExtraOrdinary | -7.2 | -21.3 | -10.6 | -5.5 | -4.9 | -16.5 | -142.5 | -137.9 | -674.3 | -590.7 | -215 | -654.6 | -2,939.5 | |
Number Of Shares End | 1 | 0.9 | 0.9 | 0.8 | 0.8 | 0.2 | 0 | 0 | 0 | 0 | ||||
Net Income Continuing Discontinued Operations | -6.8 | -17.8 | -13.4 | -4.9 | -4.3 | -12.1 | -5.9 | -2.3 | -5.2 | -3.3 | -4.1 | -5.3 | -4.3 | |
Normalized Income | -6.7 | -17.8 | -6.6 | -4.5 | -4.1 | -2.8 | -5.2 | -2.2 | -5.1 | -3.3 | -4.1 | -5.3 | -4.3 | |
Interest Income | 0.1 | 0.1 | 0.1 | |||||||||||
Interest | 0 | 0 | 0 | - | - | - | ||||||||
Net Interest Income | 0.1 | 0.1 | 0.1 | -0 | -0.6 | -0 | -0 | -0.1 | ||||||
EBIT | -6.8 | -17.6 | -13.2 | -4.9 | -4.3 | -12.1 | -5.9 | -2.3 | -5.2 | -3.3 | -4 | -5.3 | -4.3 | |
EBITDA | -6.7 | -17.5 | -13.2 | -4.9 | -4.3 | -12 | -5.8 | -2.2 | -5 | -3.2 | -3.9 | -5.2 | -4.2 | |
Reconciled Cost Of Rev. | - | - | - | - | - | - | - | - | - | - | - | - | - | |
Reconciled Depr. | 0 | 0 | 0 | 0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | ||
Profit From Continuing Operations | -6.8 | -17.8 | -13.4 | -4.9 | -4.3 | -12.1 | -5.9 | -2.3 | -5.2 | -3.3 | -4.1 | -5.3 | -4.3 | |
Normalized EBITDA | -6.7 | -17.5 | -6.4 | -4.5 | -4.1 | -2.8 | -5.1 | -2 | -5 | -3.1 | -3.9 | -5.2 | -4.2 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
TransCode Therapeutics Inc competitor comparison and performance snapshot within industry
TransCode Therapeutics Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEUTRAL
Annual Revenue TransCode Therapeutics Inc Annual Revenue is $0 Million which is growth of 0% YoY.
- NEGATIVE
Annual Net Profit TransCode Therapeutics Inc Annual Net Profit is $-35 Million which is growth of -106.9% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | TTM | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|
- | - | ||||||||||
Cost Of Rev. Ann. | - | - | - | - | - | - | - | - | - | ||
Gross Profit Ann. | - | - | - | - | - | - | - | - | - | ||
Operating Exp. Ann. | 0.6% | 91.2% | 34.8 | 17.9 | 15.1 | 18.5 | 17.6 | 5.9 | 0.7 | 0.5 | |
Operating Profit Ann. | - | - | -34.8 | -17.9 | -15.1 | -18.5 | -17.6 | -5.9 | -0.7 | -0.5 | |
- | - | 0.2 | 0.1 | -0.6 | -0.1 | 0 | -0.1 | -0.4 | -0.2 | ||
Other Exp. Ann. | - | - | -16.6 | -1 | - | - | -0.9 | -1.2 | 0 | ||
PBT Ann. | - | - | -42.4 | -34.4 | -16.8 | -18.6 | -17.6 | -6.8 | -2.3 | -0.6 | |
Tax Ann. | - | - | 0.2 | - | - | - | - | ||||
- | - | -46.3 | -36.3 | -16.8 | -18.6 | -17.6 | -6.8 | -2 | -0.5 | ||
Diluted NI Avail to Com Stockholders Ann. | - | - | -46.3 | -36.3 | -16.8 | -18.6 | -17.6 | -6.8 | -2 | -0.5 | |
EPS Ann. | - | - | -52.6 | -1,319.9 | -27,313.8 | -1,033,233.4 | -402,552.9 | -121,832.5 | -28,140.4 | ||
Diluted EPS Ann. | - | - | -52.6 | -1,319.9 | -27,313.8 | -1,033,233.4 | -402,552.9 | -121,832.5 | -28,140.4 | ||
Number Of Shares End | - | - | 0.9 | 0 | - | ||||||
Total Exp. Ann. | 0.6% | 91.2% | 17.9 | 15.1 | 18.5 | 17.6 | 5.9 | 0.7 | 0.5 | ||
Net Income Continuing Discontinued Operations Ann. | - | - | -42.8 | -34.7 | -16.8 | -18.6 | -17.6 | -6.8 | -2.3 | -0.6 | |
Normalized Income Ann. | - | - | -35.7 | -22.3 | -15.8 | -18.6 | -17.6 | -6 | -1.1 | -0.6 | |
Interest Income Ann. | - | - | 0.2 | 0.1 | 0 | 0 | |||||
Interest Ann. | - | - | 0 | 0 | 0 | 0.1 | 0.1 | 0.4 | 0.2 | ||
EBITDA Ann. | - | - | -42.3 | -34.3 | -16.2 | -18 | -17.5 | -6.7 | -2 | -0.5 | |
Reconciled Cost Of Rev. Ann. | - | - | - | - | - | - | - | - | - | ||
Reconciled Depr. Ann. | 0% | - | 0.1 | 0.1 | 0.5 | 0.5 | 0.1 | 0 | - | - | |
Profit From Continuing Operations Ann. | - | - | -42.8 | -34.7 | -16.8 | -18.6 | -17.6 | -6.8 | -2.3 | -0.6 | |
Normalized EBITDA Ann. | - | - | -35.1 | -17.7 | -15.2 | -18 | -17.5 | -5.8 | -0.7 | -0.5 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Operating Exp. Ann.
1Y CHG
18.5%
2Y CAGR
-1.6%
3Y CAGR
0.6%
5Y CAGR
91.2%
TransCode Therapeutics Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- POSITIVE
Total Shareholders Fund TransCode Therapeutics Inc Dec-2025 Total Shareholders Fund is $10 Million which is growth of 612.0% YoY.
- POSITIVE
Total Assets TransCode Therapeutics Inc Dec-2025 Total Assets is $162 Million which is growth of 2126.3% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 |
|---|---|---|---|---|---|---|---|---|---|---|
177.5% | 171.5% | 162.4 | 7.3 | 5.2 | 7.6 | 22.9 | 1.1 | 0.2 | ||
33.6% | 18.5% | 10.5 | 9.3 | 3.5 | 4.4 | 2.5 | 4.5 | 1.3 | ||
47.6% | - | 10.3 | -2 | 1.6 | 3.2 | 20.4 | -3.4 | -1.1 | ||
Total Capitalization Ann. | 262.1% | - | 151.9 | -2 | 1.6 | 3.2 | 20.4 | -1.3 | -0.2 | |
Tangible Assets Ann. | 54.5% | - | 11.8 | -2 | 1.6 | 3.2 | 20.4 | -3.4 | -1.1 | |
Working Capital Ann. | 83.4% | 115.3% | 18.5 | 4.3 | 1 | 3 | 20.2 | 0.4 | 0.1 | |
Invested Capital Ann. | 47.6% | - | 10.3 | -2 | 1.6 | 3.2 | 20.4 | -1.3 | -0.2 | |
Tangible Book Value Ann. | - | - | -129.7 | -2 | 1.6 | 3.2 | 20.4 | -3.4 | -1.1 | |
Borrowings Ann. | - | - | 0 | 0.5 | - | - | 2.1 | 0.9 | ||
Net Debt Ann. | - | - | - | - | - | - | - | 1.3 | 0.7 | |
Share Issued Ann. | - | - | 0.9 | 0 | ||||||
Number Of Shares End | - | - | 0.9 | 0 | - |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
2124.7%
2Y CAGR
458.8%
3Y CAGR
177.5%
5Y CAGR
171.5%
Total Current Liabilities Ann.
1Y CHG
25%
3Y CAGR
-7.3%
5Y CAGR
54.3%
Total ShareHolders Funds Ann.
2Y CAGR
153.7%
3Y CAGR
47.6%
TransCode Therapeutics Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEGATIVE
Book Value Per Share TransCode Therapeutics Inc Book Value Per Share is $2 which is growth of -96.5% YoY.
- NEUTRAL
ROE TransCode Therapeutics Inc ROE is 0% which is growth of 0% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 |
|---|---|---|---|---|---|---|---|---|---|---|
RoA Ann. % | - | - | - | -269.34% | -290.74% | -115.08% | -57.04% | -309.46% | -220.20% | |
ROE Ann. % | - | - | - | - | -759.85% | -148.57% | -80.53% | - | - | |
ROIC % | - | - | - | - | -114.7 | -89.6 | -12.9 | - | - | |
OPM Ann. % | - | - | - | - | - | - | - | - | - | |
Inventory Turnover Ratio Ann. | - | - | - | - | - | - | - | - | - | |
Asset Turnover Ann. % | - | - | - | - | - | - | - | - | - | |
Working Capital Turnover Ann. | - | - | ||||||||
Quick Ratio Ann. | 65.1% | 20.8% | 5.4 | 2.1 | 0.8 | 1.2 | 8.2 | 2.1 | 3.3 | |
Current Ratio Ann. | - | - | - | 2.6 | 1.3 | 1.7 | 9 | 2.1 | 3.3 | |
Interest Coverage Ratio Ann. | - | - | - | -623.9 | -330.8 | - | -71 | -4.9 | -2.9 | |
LT Debt To Equity Ann. | - | - | - | - | 0 | - | - | - | - |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
TransCode Therapeutics Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEGATIVE
Cash From Operating Activity TransCode Therapeutics Inc Cash From Operating Activity is $-20 Million which is growth of -46.3% YoY.
- POSITIVE
Net Cash Flow TransCode Therapeutics Inc Net Cash Flow is $12 Million which is growth of 294.4% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 |
|---|---|---|---|---|---|---|---|---|---|---|
- | - | -19.5 | -13.3 | -18.1 | -15.8 | -5.3 | -0.5 | -0.5 | ||
- | - | -0 | -0 | -0.1 | -0.3 | - | - | |||
- | 95.6% | 31.5 | 16.4 | 15.9 | 0 | 25.5 | 1.1 | 0.5 | ||
Cash Plus Cash Eqv. End Of Year Ann. | 52.7% | 86% | 17.8 | 5.8 | 2.8 | 5 | 20.8 | 0.8 | 0.2 | |
Net Increase In Cash Plus Cash Eqv.s Ann. | - | 82.1% | 12 | 3 | -2.2 | -15.9 | 20 | 0.6 | -0 | |
Cash Plus Cash Eqv. Begin Of Year Ann. | -34.7% | 96.1% | 5.8 | 2.8 | 5 | 20.8 | 0.8 | 0.2 | 0.2 | |
Income Tax Paid Supplemental Data Ann. | - | - | - | - | - | - | ||||
Interest Paid Supplemental Data Ann. | - | - | 0 | 0 | 0 | 0 | 0 | |||
Capex Ann. | - | - | -0 | -0 | -0 | -0.1 | -0.3 | - | - | |
Issuance Of Capital Stock Ann. | - | - | 31.5 | 16.4 | 15.9 | 26.3 | - | - | ||
Issuance Of Debt Ann. | - | - | - | - | - | - | 1.2 | 0.5 | ||
Repayment Of Debt Ann. | - | - | - | - | - | - | - | - | - | |
Repurchase Of Capital Stock Ann. | - | - | - | - | - | - | - | - | - | |
Free Cash Flow Ann. | - | - | -19.5 | -13.4 | -18.1 | -15.9 | -5.5 | -0.5 | -0.5 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Financing Act. Ann.
1Y CHG
92.1%
2Y CAGR
40.8%
5Y CAGR
95.6%